Epitome Therapeutics
Summary active Updated Jun 30, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Epitome Therapeutics is a Vienna-based biotech company developing precision epigenome editing technology for programmable gene expression 12. Founded in 2025 as a spin-out from the European Molecular Biology Laboratory (EMBL), Epitome’s proprietary CADENCE platform enables precise, durable activation of endogenous genes without altering the underlying DNA sequence 12. The company was co-founded by Guido Gualdoni (Co-Founder & CEO) and Jamie Hackett (Co-Founder & Chief Scientific Officer), and is leveraging research from EMBL Rome published in Nature Genetics 12. Epitome intends to use the new financing to advance therapeutic programs and grow its team 12.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-30 | Pre-Seed | €4M | XISTA Science Ventures, Caesar Ventures | Navec Venture Holding 12 |
The €4M total comprises an oversubscribed €2M pre-seed equity round co-led by XISTA Science Ventures and Caesar Ventures, plus €2M in non-dilutive grant funding 12.
What Investors Say
“We were impressed by the breakthrough nature of Epitome Therapeutics’ approach to epigenome editing, especially its focus on targeted upregulation.” — Alexander Schwartz, XISTA Science Ventures, quoted in the June 30, 2026 announcement 2
What Founders Say
“Completing an oversubscribed financing is a strong endorsement of both our team and the potential of the CADENCE platform.” — Guido Gualdoni, Co-Founder & CEO, Epitome Therapeutics, quoted in the June 30, 2026 announcement 2
Sources
-
BeBeez International, “Austrian BioTech startup Epitome Therapeutics announces €4 million in funding to advance programmes and grow team,” June 30, 2026. Accessed June 2026. https://bebeez.eu/2026/06/30/austrian-biotech-startup-epitome-therapeutics-announces-e4-million-in-funding-to-advance-programmes-and-grow-team/↩↩↩↩↩↩
-
EU-Startups, “Austrian BioTech startup Epitome Therapeutics announces €4 million in funding to advance programmes and grow team,” June 30, 2026. Accessed June 2026. https://www.eu-startups.com/2026/06/austrian-biotech-startup-epitome-therapeutics-announces-e4-million-in-funding-to-advance-programmes-and-grow-team/↩↩↩↩↩↩↩↩